NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $18.38M rose 21.1% year over year, ahead of the -16.1% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +143.5% a year.
Context
- Stock-based compensation amounted to 264.1% of revenue in FY2025, up 190.3 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +21.1% holds above the trailing-twelve-month pace of -16.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 59.43M USD
- Year-over-year change
- +76.8%
- 4-year CAGR
- +162.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.43M | +76.8% |
| FY2024 | 2024-12-31 | 33.62M | +36.8% |
| FY2023 | 2023-12-31 | 24.57M | +496.8% |
| FY2022 | 2022-12-31 | 4.12M | +230.9% |
| FY2021 | 2021-12-31 | 1.24M | — |
Stock-Based Compensation vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.1% is the lowest of 9, against a peer median of +14.3%.
- Stock-based compensation amounts to 468.9% of revenue for NAMS, versus a peer median of 20.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $95.64M USD | +17.1% | +45.9% | 7.4% | |
| LTM Jun 2026 | $69.95M USD | +39.2% | -0.1% | 1941.0% | |
| LTM Jun 2026 | $37.39M USD | -5.4% | +67.6% | — | |
| LTM Jun 2026 | $33.39M USD | -16.1% | +143.5% | 468.9% | |
| LTM Sep 2026 | $31.2M USD | +11.4% | +8.4% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $19.67M USD | +177.6% | +77.3% | 20.4% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $13M USD | +43.2% | +66.3% | 126.0% |
| LTM Mar 2026 | $9.77M USD | +1.5% | +47.6% | — | |
| FY2025 | A$979.92K AUD | +11.1% | -13.3% | 18.0% | |
| Peer median (excluding NAMS) | — | +14.3% | +46.8% | 20.4% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.24M | 4.12M | 24.57M | 33.62M | 59.43M |
| Change in Working Capital | 4.47M | 10.37M | 5.87M | (32.67M) | (7.94M) |
| Accounts Receivables | 0 | (4.18M) | 4.03M | 0 | (13.28M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 6.56M | 4.81M | 5.07M | (12.95M) | 4.91M |
| Other Working Capital | (2.09M) | 9.75M | (3.23M) | (19.73M) | 427K |
| Other Non-Cash Items | 6.55M | 18.8M | 5.23M | 81.98M | 4.34M |
| Operating Cash Flow | (29.51M) | 10.67M | (141.22M) | (158.56M) | (147.78M) |
| Capital Expenditures | (24K) | (221K) | (24K) | (672K) | (246K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (62.18M) | (296.73M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 122.06M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (24K) | (221K) | (24K) | (62.85M) | (174.92M) |
| Debt Repayment | 0 | 747K | 0 | 0 | 0 |
| Common Stock Issued | 84.7M | 396.95M | 8.91M | 645.51M | 29.52M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (5.79M) | 0 | 14M | 0 |
| Financing Cash Flow | 84.7M | 391.91M | 8.91M | 659.51M | 29.52M |
| Effect of Forex Changes | (4.68M) | 5.25M | 5.05M | (6.8M) | 12.76M |
| Net Change in Cash | 50.49M | 407.6M | (127.28M) | 431.29M | (280.42M) |
| Free Cash Flow | (29.54M) | 10.44M | (141.24M) | (159.24M) | (148.03M) |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.